Bristol Myers Squibb Company Plans Quarterly Dividend of $0.63 (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) announced a quarterly dividend on Wednesday, June 17th. Shareholders of record on Thursday, July 2nd will be given a dividend of 0.63 per share by the biopharmaceutical company on Monday, August 3rd. This represents a c) annualized dividend and a yield of 4.5%. The ex-dividend date of this dividend is Thursday, July 2nd.

Bristol Myers Squibb has increased its dividend payment by an average of 0.0%per year over the last three years and has raised its dividend annually for the last 17 consecutive years. Bristol Myers Squibb has a payout ratio of 41.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Bristol Myers Squibb to earn $6.05 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.7%.

Bristol Myers Squibb Stock Down 0.9%

Shares of NYSE:BMY opened at $55.41 on Thursday. The company’s fifty day moving average is $57.52 and its two-hundred day moving average is $57.08. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The stock has a market capitalization of $113.15 billion, a price-to-earnings ratio of 15.56, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the business posted $1.80 EPS. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb will post 6.32 EPS for the current year.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported positive Phase III SUCCESSOR-2 data in multiple myeloma and highlighted early clinical success for a CAR T-cell therapy, reinforcing optimism around its oncology pipeline. Bristol Myers Squibb (BMY) Unveils Myeloma Trial Win And New Gulf Leadership
• Positive Sentiment: The company declared a quarterly dividend of $0.63 per share, which keeps BMY attractive to income-focused investors and supports the stock’s dividend yield profile. Bristol Myers Squibb Announces Dividend
• Positive Sentiment: Analysts and market commentary continue to point to potential undervaluation tied to pipeline strength and margin improvement, which may be helping support sentiment. Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes
• Neutral Sentiment: Bristol Myers Squibb said it will report second-quarter 2026 results on July 30, a routine catalyst that could move the shares depending on guidance and sales trends. Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
• Neutral Sentiment: The company also appointed a new general manager for Saudi Arabia and Gulf countries, a regional management move that is unlikely to affect the stock materially in the near term. Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries
• Negative Sentiment: Recent trading has been soft, with shares showing weakness over the past month and quarter, suggesting investors remain cautious despite the positive pipeline headlines. Bristol Myers Squibb (BMY) Stock Moves -1.14%: What You Should Know

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.